Synairgen plc (AIM: SNG)

London flag London · Delayed Price · Currency is GBP · Price in GBX
4.700
+0.445 (10.46%)
Oct 9, 2024, 3:35 PM GMT+1
-37.67%
Market Cap 8.57M
Revenue (ttm) n/a
Net Income (ttm) -6.92M
Shares Out 201.37M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 123,761
Open 3.975
Previous Close 4.255
Day's Range 3.975 - 4.700
52-Week Range 3.000 - 11.000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Sep 20, 2024

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 36
Stock Exchange London Stock Exchange AIM
Ticker Symbol SNG
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.